Navigation Links
AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Date:11/24/2009

others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.

SOURCE AETERNA ZENTARIS INC.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 SoundConnect, ... collaboration company is dedicated to supporting business communication ... Julie Power, a carrier services ... collaboration solutions stays connected and productive at all ... increased movement of businesses to cloud communications services. ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview with ... that he will lead on “Stem Cells” at the ... in London. In the interview posted online ... to several questions on the current state of technologies for ... and future trends in the use of stem cells for ...
(Date:9/30/2014)... New Jersey (PRWEB) September 30, 2014 ... it has been chosen by the Parenteral Drug ... (November 18 and 19, 2014) on container closure integrity ... container closure integrity test methods and philosophies detailed in ... – Integrity Evaluation. The course will span ...
(Date:9/30/2014)... Pittsburgh PA (PRWEB) September 30, 2014 ... Nurses ( IACRN), a non-profit organization based ... Clinical Research Excellence and Safety (ACRES), a ... of a strategic alliance agreement, setting the stage ... is to enhance clinical research quality and safety ...
Breaking Biology Technology:SoundConnect Expands Carrier Services Division 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... study of single-agent carfilzomib, a next generation proteasome inhibitor, ... achieved an overall response rate (ORR) (partial response or ... response (DOR) of 8.3 months in patients who entered ...
... show scientists the way to make batches of nanotubes of ... Physical Review Letters unveils an elegant formula by ... the energy of a piece of graphene cut at any ... materials science and of chemistry, said this alone is significant ...
... 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... the first 60 patients enrolled in the Phase I/II trial ... reported today in an oral presentation at the 52nd American ... Florida. "Anemia is the most serious symptom associated ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 2Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 3Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 4Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 5Pure nanotube-type growth edges toward the possible 2Pure nanotube-type growth edges toward the possible 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6
(Date:9/29/2014)... PULLMAN, Wash. Scientists at Washington State University ... specifically, Granny Smith apples may help prevent ... be the first to assess these compounds in ... in October,s print edition of the journal ... apples are a good source of these nondigestible ...
(Date:9/29/2014)... decades, planetary geologists have speculated that glaciers might ... chasm that constitutes the Grand Canyon of Mars. ... might have been carved by past glaciers as ... have remained highly controversial and contested. , ... and the Freie Universitaet Berlin has identified what ...
(Date:9/29/2014)... found that a combination of a real-time feedback system ... of residence resulted in a reduction of 37% in ... were 1360.49 kWh, which is equivalent to a reduction ... weeks. , In contrast, another eight halls, exposed ... alert, resulted in saw a 3.5% reduction in energy ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2Glaciers in the Grand Canyon of Mars? 2Glaciers in the Grand Canyon of Mars? 3Glaciers in the Grand Canyon of Mars? 4Glaciers in the Grand Canyon of Mars? 5Glaciers in the Grand Canyon of Mars? 6Glaciers in the Grand Canyon of Mars? 7Glaciers in the Grand Canyon of Mars? 8Glaciers in the Grand Canyon of Mars? 9
... NY-- The Damon Runyon Cancer Research Foundation named ... 2008 Fellowship Award Committee review. The recipients ... scientists conducting basic and translational cancer research in ... country. The Fellowship is specifically intended to ...
... is available in French . , McGill ... of the world leading pioneers in green chemistry, an entirely ... toxic, petrochemical-based solvents in favour of basic substances like water ... of the green approach are obvious and significant, but following ...
... Industry scientists and international collaborators have discovered the key ... years cost wheat growers worldwide in excess of AUS$7.8 ... prestigious journal Science , scientists from CSIRO Plant ... and Wheat Improvement Center have identified a wheat gene ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 4Peptides-on-demand: McGill researcher's radical new green chemistry makes the impossible possible 2Saving wheat crops worldwide 2
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Request Info...
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
... This goat anti-rabbit IgG FITC ... antibody' for immunofluorescent staining on tissues ... antibody is generated in rabbits. It ... controls, such as omitting the primary ...
Biology Products: